Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
06:47pm, Tuesday, 17'th Oct 2023
Pfizer (PFE) concluded the recent trading session at $32.75, signifying a -1.56% move from its prior day's close.
Why Pfizer Stock Slipped Today
06:10pm, Tuesday, 17'th Oct 2023
Two analysts reduced their price targets on the pharmaceutical giant. One cut was deep, the other very shallow.
35 September Readers-Noted, And 27 Ideal-To-Buy, Dividend Dogs
03:39pm, Tuesday, 17'th Oct 2023
Prior to September 30, 2023, my Readers mentioned 35 equities in their comments on my articles. Some bad news investments (Rogues) mixed with (mostly) Favorites. Thus, these are ReFa/Ro. Ten analyst-t
Pfizer Looks for a Covid Bottom
06:00am, Tuesday, 17'th Oct 2023
The pharma giant has had to slash projections, but investors welcome its plans to cut costs.
Markets Pop on Bargain Hunting, Stronger Economy
08:18pm, Monday, 16'th Oct 2023
The small-cap Russell 2000, still under water over the past month, led the way higher today.
Paxlovid contract renegotiation pushed Covid business over the edge, says BMO's Evan Seigerman
06:11pm, Monday, 16'th Oct 2023
Evan Seigerman, BMO Capital Markets analyst, joins 'Closing Bell: Overtime' to discuss Pfizer and BioNTech cutting guidance amid Covid sales falling, the weight loss boom, and more.
Pfizer confronts ‘peak of anti-vaccination rhetoric' as shares rebound
11:05am, Monday, 16'th Oct 2023
Pfizer Inc. PFE, +5.52% on Monday sought to reassure investors that it can slash costs to repair the damage done by underwhelming COVID-19 product sales.
Pfizer Stock Brushes Off Forecast Cut on Analyst Upgrade
10:51am, Monday, 16'th Oct 2023
The shares of Pfizer Inc (NYSE:PFE) have reversed their premarket losses, up 4.5% at $33.57 at last glance.
Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls
10:32am, Monday, 16'th Oct 2023
Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.
Pfizer cuts guidance on slumping COVID vaccine, treatment sales
10:07am, Monday, 16'th Oct 2023
"Pfizer (PFE) lowered its 2023 sales forecast on waning COVID vaccine demand, but analysts say cost cuts and new drug launches can drive growth. Yahoo Finance's Seana Smith reports on how low demand f
Moderna confirms COVID sales guidance as shares sink on Pfizer news
09:37am, Monday, 16'th Oct 2023
With its shares under pressure due to revised COVID guidance from Pfizer Inc. PFE, +3.38%, Moderna Inc. MRNA, -3.19% on Monday said it “remains comfortable” with its existing guidance on full-year
2 Big-Name Stocks Making Monday Morning Moves
09:11am, Monday, 16'th Oct 2023
Stocks were poised to gain some ground early Monday. Lululemon Athletica will become part of the S&P 500 index.
Pfizer's earnings cut was 'sort of telegraphed', says E Squared's Les Funtleyder
08:52am, Monday, 16'th Oct 2023
Les Funtleyder, E Squared Capital Management healthcare portfolio manager, joins 'Squawk Box' to discuss Pfizer cutting full-year revenue guidance by $9 billion, after the pharmaceutical giant said dw
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand
07:18am, Monday, 16'th Oct 2023
Pfizer slashed its revenue forecasts on Friday amid falling demand for its Covid vaccine and antiviral drug Paxlovid.
Pfizer and BioNtech take big write-downs on Covid jab stocks
06:21am, Monday, 16'th Oct 2023
Covid vaccine developer BioNTech is to take a write-down of up to €900 million on its stocks of jabs following a similar provision by partner Pfizer last week. Pfizer had said that the write-offs r
